11. Vaccines for a Global Community: Meningococcus A and B, Cholera, and Malaria
Thursday, October 20, 2011: 12:30 PM-2:30 PM
Room: 205ABC

Learning Objectives:

At the conclusion of this session, participants will be able to: 


  • recognize the burden of illness associated with malaria, cholera, dengue and Japanese encephalitis, and the risk for patients travelling to areas where these illnesses occur
  • define which of these diseases are now, or are likely to be, vaccine-preventable in the near future
  • recommend to patients when they should be immunized against these diseases

Target Audience: Travel Medicine Specialists, Vaccinologists, Scientists, Researchers, Public Health Practitioners, Pharmacists, Nurses, Lab Personnel, Investigators, Infectious Diseases Physicians, Infectious Diseases Pediatricians, Infection Preventionists, Health Care Workers, Fellows-in-Training, Epidemiologists, Clinicians, Academicians

Tracks: Global ID, Pediatric ID, Adult ID

Moderators:  Joanne Langley, MD, Dalhousie University and Bruce Gellin, MD, MPH, Department of Health and Human Services


ACPE Credits: ACPE 2.0 knowledge-based contact hours (0.2 CEU) of Pharmacy CE

ACPE Number: 0461-9999-11-092-L01-P


J. Langley, sanofi pasteur, novartis, pfizer: Grant Investigator, Research grant

B. Gellin, None

F. M. LaForce, None

R. Rappuoli, Novartis Vaccines: Employee, Salary

M. Levine, PaxVax: License agreement with PaxVax to develop, manufacture and commercialize vaccines from CVD 103-HgR developed in the CVD of which I am co-inventor of one of the candidates. If product is sold some royalties could come to the University of Maryland or me., Licensing agreement or royalty
AfriChol (AMP & AFENET): Scientific Advisor, Travel Reimbursement

C. Loucq, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.